Wyszuk. zaawans.

Tom 5, Supl. II (2020)
Suplement
Opublikowany online: 2020-05-22

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 439
Wyświetlenia/pobrania artykułu 588
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Wartość uzupełniającego leczenia trastuzumabem chorych na raka piersi w Polsce w latach 2008–2015

Beata Jagielska1

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Didkowska J, Wojciechowska U, Czaderny K. et al. Nowotwory złośliwe w Polsce w 2017 roku. Ministerstwo Zdrowia, Warszawa 2019.
  2. Gallagher CM, More K, Masaquel A, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32(33): 3744–3752.
    CrossRefPubMed
  3. Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273–1283.
    CrossRefPubMed
  4. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008; 26(20): 3324–3330.
    CrossRefPubMed
  5. Han W, Kim SW, Park InAe, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004; 4: 82.
    CrossRefPubMed
  6. Lee MK, Varzi LA, Chung DU, et al. The Effect of Young Age in Hormone Receptor Positive Breast Cancer. Biomed Res Int. 2015; 2015: 325715.
    CrossRefPubMed
  7. Dubsky PC, Gnant MFX, Taucher S, et al. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer. 2002; 3(1): 65–72.
    CrossRefPubMed
  8. Beadle BM, Woodward WA, Buchholz TA. The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol. 2011; 21(1): 26–34.
    CrossRefPubMed
  9. Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. Semin Oncol. 2009; 36(3): 237–249.
    CrossRefPubMed
  10. Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005; 18(10): 1305–1320.
    CrossRefPubMed
  11. Cancello G, Montagna E. Treatment of breast cancer in young women: do we need more aggressive therapies? J Thorac Dis. 2013; 5 Suppl 1: S47–S54.
    CrossRefPubMed
  12. van der Groep P, Bouter A, van der Zanden R, et al. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2004; 96(9): 712–713; author reply 714.
    CrossRefPubMed
  13. Partridge AH, Gelber S, Piccart-Gebhart MJ, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013; 31(21): 2692–2698.
    CrossRefPubMed
  14. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(8): 1194–1220.
    CrossRef
  15. Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals of Oncology. 2019; 30(10): 1541–1557.
    CrossRef
  16. Balic M, Thomssen C, Würstlein R, et al. St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. Breast Care (Basel). 2019; 14(2): 103–110.
    CrossRefPubMed
  17. O'Sullivan CC, Bradbury I, Campbell C, et al. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol. 2015; 33(24): 2600–2608.
    CrossRefPubMed
  18. Didkowska J. Mammography screening — a recognised standard. NOWOTWORY J Oncol. 2017; 66(5): 418–421.
    CrossRef
  19. Jassem J, Krzakowski M, Bobek-Billewicz B, et al. Rak piersi. Onkol Prakt Klin Edu. 2018; 4(4): 209–256.
  20. Carioli G, Malvezzi M, Rodriguez T, et al. Trends and predictions to 2020 in breast cancer mortality in Europe. Breast. 2017; 36: 89–95.
    CrossRefPubMed
  21. Wojciechowska U, Wesołowska E, Olszewski W, et al. Wybrane zagadnienia z patologii raka piersi. Ginekologia po dyplomie. 2015; 5: 1–19.
  22. Wojciechowska U, Czaderny K, Ciuba A. et al. Nowotwory złośliwe w Polsce w 2016 roku. Cancer in Poland in 2016. Ministerstwo Zdrowia, Warszawa 2018.
  23. Castanon A, Sasieni P. Is the recent increase in cervical cancer in women aged 20-24years in England a cause for concern? Prev Med. 2018; 107: 21–28.
    CrossRefPubMed
  24. Dębski R. Hormonalna terapia zastępcza a rak sutka. Postępy Nauk Medycznych. 2008; 4: 240–245.
  25. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990; 97(12): 1080–1086.
    CrossRefPubMed
  26. Bonnier P, Bessenay F, Sasco AJ, et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer. 1998; 79(3): 278–282.
    CrossRefPubMed
  27. Colditz G, Hankinson S, Hunter D, et al. The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women. N Engl J Med. 1995; 332(24): 1589–1593.
    CrossRef
  28. Anderson GL, Judd HL, Kaunitz AM, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003; 290(13): 1739–1748.
    CrossRefPubMed
  29. Chlebowski RT, Hendrix SL, Langer RD, et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289(24): 3243–3253.
    CrossRefPubMed
  30. Gravena AA, Romeiro Lopes TC, Demitto Md, et al. The Obesity and the Risk of Breast Cancer among Pre and Postmenopausal Women. Asian Pac J Cancer Prev. 2018; 19(9): 2429–2436.
    CrossRefPubMed
  31. Huszno J, Kołosza Z, Grzybowska E. mutation in breast cancer patients: Analysis of prognostic factors and survival. Oncol Lett. 2019; 17(2): 1986–1995.
    CrossRefPubMed
  32. Jassem J, Krzakowski M, Bobek-Billewicz B, et al. Breast cancer. Oncol Clin Pract. ; 2018: 14.
    CrossRef
  33. Foulkes WD, Chappuis PO, Wong N, et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol. 2000; 11(3): 307–313.
    CrossRefPubMed
  34. Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017; 4(1).
    CrossRefPubMed
  35. Templeton AJ, Gonzalez LD, Vera-Badillo FE, et al. Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. PLoS One. 2016; 11(5): e0154789.
    CrossRefPubMed
  36. Balmaña J, Díez O, Rubio IT, et al. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22: vi31–vi34.
    CrossRef
  37. Narodowa Strategia Onkologiczna. https://www.gov.pl/web/zdrowie/narodowa-strategia-onkologiczna.
  38. Narodowy Program Zwalczania Chorób Nowotworowych Ministerstwa Zdrowia. https://www.gov.pl/web/zdrowie/modul-i-wczesne-wykrywanie-nowotworow-zlosliwych-w-rodzinach-wysokiego-dziedzicznie-uwarunkowanego-ryzyka-zachorowania-na-raka-piersi-i-raka-jajnika-na-lata-2019-2021.
  39. Schneble EJ, Graham LJ, Shupe MP, et al. Future directions for the early detection of recurrent breast cancer. J Cancer. 2014; 5(4): 291–300.
    CrossRefPubMed
  40. Leong ASY, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 2011; 78(2): 99–114.
    CrossRefPubMed
  41. Viale G. The current state of breast cancer classification. Annals of Oncology. 2012; 23: x207–x210.
    CrossRef
  42. Iorfida M, Maiorano E, Orvieto E, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat. 2012; 133(2): 713–723.
    CrossRefPubMed
  43. Huang HJ, Neven P, Drijkoningen M, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005; 58(6): 611–616.
    CrossRefPubMed
  44. Wolff AC, Hammond ME, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018; 142(11): 1364–1382.
    CrossRefPubMed
  45. Murray C, Flanagan L, D'Arcy C, et al. Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? ASCO/College of American Pathologists Guidelines 2007, 2013, and 2018. J Clin Oncol. 2018 [Epub ahead of print]; 143(4): JCO1800788–413.
    CrossRefPubMed
  46. Paik HJ, Choi H, Ryu J, et al. Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results. Breast. 2018; 6(1): 1–10.
    CrossRef
  47. Liu ZH, Wang K, Lin DY, et al. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases. Breast Cancer Res Treat. 2019; 175(1): 51–57.
    CrossRefPubMed
  48. Debeb YG, Berihu BA. Review on the role of estrogen receptors in breast cancer. Int J Pharma Sciences Research. ; 2015: 6.
  49. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747–752.
    CrossRefPubMed
  50. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006; 7: 96.
    CrossRefPubMed
  51. Bagaria SP, Ray PS, Sim MS, et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg. 2014; 149(2): 125–129.
    CrossRefPubMed
  52. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101(10): 736–750.
    CrossRefPubMed
  53. Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(4): 290–303.
    CrossRefPubMed
  54. Rakha EA, Reis-Filho JS, Ellis IO. Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology. 2008; 75(2): 95–103.
    CrossRefPubMed
  55. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004; 203(2): 661–671.
    CrossRefPubMed
  56. Chanrion M, Fontaine H, Rodriguez C, et al. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. BMC Cancer. 2007; 7: 39.
    CrossRefPubMed
  57. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005; 116(3): 340–350.
    CrossRefPubMed
  58. Makretsov NA, Huntsman DG, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res. 2004; 10(18 Pt 1): 6143–6151.
    CrossRefPubMed
  59. Dolled-Filhart M, Rydén L, Cregger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 2006; 12(21): 6459–6468.
    CrossRefPubMed
  60. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006; 208(4): 495–506.
    CrossRefPubMed
  61. Savage K, Lambros MBK, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007; 13(1): 90–101.
    CrossRefPubMed
  62. Yehiely F, Moyano JV, Evans JR, et al. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006; 12(11): 537–544.
    CrossRefPubMed
  63. Tischkowitz M, Brunet JS, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007; 7: 134.
    CrossRefPubMed
  64. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19): 10869–10874.
    CrossRefPubMed
  65. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14): 8418–8423.
    CrossRefPubMed
  66. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997; 57(7): 1222–1227.
    PubMed
  67. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11(16): 5678–5685.
    CrossRefPubMed
  68. Koh J, Kim MJ. Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. Korean J Radiol. 2019; 20(1): 69–82.
    CrossRefPubMed
  69. Xiao M, Yang Z, Tang X, et al. Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast. Oncol Lett. 2017; 14(2): 1971–1978.
    CrossRefPubMed
  70. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67(2): 93–99.
    CrossRefPubMed
  71. Lange S, Scheibler F, Fleer D, et al. Interpretation of the Results of the MINDACT Study and Consequent Recommendations in the Updated ASCO Clinical Practice Guideline. J Clin Oncol. 2018; 36(4): 429–430.
    CrossRefPubMed
  72. Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(4): 290–303.
    CrossRefPubMed
  73. BLOOM HJ, RICHARDSON WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11(3): 359–377.
    CrossRefPubMed
  74. Lipponen P, Aaltomaa S, Eskelinen M, et al. The changing importance of prognostic factors in breast cancer during long-term follow-up. Int J Cancer. 1992; 51(5): 698–702.
    CrossRefPubMed
  75. Decker T, Hungermann D, Böcker W. [Prognostic and predictive factors of invasive breast cancer: update 2009]. Pathologe. 2009; 30(1): 49–55.
    CrossRefPubMed
  76. Matkowski R. Wartość prognostyczna ekspresji receptora estrogenowego i produktu genu nm23 w komórkach raka przewodowego piersi i ich korelacja z wybranymi parametrami klinicznymi. Rozprawa doktorska. Wrocław 2002. http://www.zdrowie.walbrzych.pl/upl/fileBrowser/medycyna-pracanaukowa-matkowski.pdf.
  77. Koscielny S, Tubiana M, Lê MG, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer. 1984; 49(6): 709–715.
    CrossRefPubMed
  78. Tubiana M, Koscielny S. Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat. 1991; 18(3): 125–140.
    CrossRefPubMed
  79. Joensuu H, Toikkanen S. Cured of breast cancer? J Clin Oncol. 1995; 13(1): 62–69.
    CrossRefPubMed
  80. Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998; 16(2): 462–469.
    CrossRefPubMed
  81. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002; 13(2): 273–279.
    CrossRefPubMed
  82. Forbes JF, Sestak I, Howell A, et al. IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016; 387(10021): 866–873.
    CrossRefPubMed
  83. Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016; 387(10021): 849–856.
    CrossRefPubMed
  84. De La Cruz L, Moody AM, Tappy EE, et al. Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review. Ann Surg Oncol. 2015; 22(10): 3241–3249.
    CrossRefPubMed
  85. Morrow M, Zee KV, Solin L, et al. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Pract Radiat Oncol. 2016; 6(5): 287–295.
    CrossRef
  86. Dobrescu A, Chang M, Kirtani V, et al. Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer. ISRN Oncol. 2011; 2011: 673790.
    CrossRefPubMed
  87. Loi S. The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. Ann Oncol. 2019; 30(8): 1183–1184.
    CrossRefPubMed
  88. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938): 164–172.
    CrossRefPubMed
  89. Peccatori FA, Azim HA, Orecchia R, et al. ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi160–vi170.
    CrossRefPubMed
  90. Association of Breast Surgery at Baso 2009. Surgical guidelines for the management of breast cancer. Eur J Surg Oncol. 2009; 35 Suppl 1: 1–22.
    CrossRefPubMed
  91. Galimberti V, Cole BF, Zurrida S, et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14(4): 297–305.
    CrossRefPubMed
  92. Giuliano AE, Ballman KV, McCall L, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305(6): 569–575.
    CrossRefPubMed
  93. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15(12): 1303–1310.
    CrossRefPubMed
  94. Darby S, McGale P, Correa C, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804): 1707–1716.
    CrossRefPubMed
  95. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014; 88(3): 553–564.
    CrossRefPubMed
  96. van Werkhoven E, Hart G, Tinteren Hv, et al. Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. Radiother Oncol. 2011; 100(1): 101–107.
    CrossRefPubMed
  97. Vrieling C, van Werkhoven E, Maingon P, et al. European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups, EORTC Radiation Oncology and Breast Cancer Groups, European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015; 16(1): 47–56.
    CrossRefPubMed
  98. Poortmans P. Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014; 383(9935): 2104–2106.
    CrossRefPubMed
  99. Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015; 114(1): 3–10.
    CrossRefPubMed
  100. McGale P, Taylor C, Correa C, et al. EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935): 2127–2135.
    CrossRefPubMed
  101. Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006; 24(30): 4888–4894.
    CrossRefPubMed
  102. Curigliano G, Burstein HJ, P Winer E, et al. Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8): 1700–1712.
    CrossRefPubMed
  103. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472): 1687–1717.
    CrossRef
  104. Del Mastro L, De Placido S, Bruzzi P, et al. Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015; 385(9980): 1863–1872.
    CrossRefPubMed
  105. Foukakis T, von Minckwitz G, Bengtsson NO, et al. Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG). Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA. 2016; 316(18): 1888–1896.
    CrossRefPubMed
  106. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009; 27(8): 1177–1183.
    CrossRefPubMed
  107. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017; 35(23): 2647–2655.
    CrossRefPubMed
  108. Cuzick J, Sestak I, Baum M, et al. ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010; 11(12): 1135–1141.
    CrossRefPubMed
  109. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28(3): 509–518.
    CrossRefPubMed
  110. Francis PA. Abstract CS1-1: Adjuvant endocrine therapy for premenopausal ER+ breast cancer. Invited Speaker Abstracts. 2018.
    CrossRef
  111. Francis PA, Pagani O, Fleming GF, et al. SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018; 379(2): 122–137.
    CrossRefPubMed
  112. Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869): 805–816.
    CrossRefPubMed
  113. Vogl SE. 8-Year Update of SOFT and TEXT Trials: Positive but Not Definitive. https://ascopost.com/issues/july-25-2018/8-year-update-of-soft-and-text-trials/.
  114. Louie MC, Sevigny MB. Steroid hormone receptors as prognostic markers in breast cancer. Am J Cancer Res. 2017; 7(8): 1617–1636.
    PubMed
  115. Wu X, Subramaniam M, Grygo SB, et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 2011; 13(2): R27.
    CrossRefPubMed
  116. Ogawa S, Inoue S, Watanabe T, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res. 1998; 26(15): 3505–3512.
    CrossRefPubMed
  117. Peng B, Lu B, Leygue E, et al. Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol. 2003; 30(1): 13–29.
    CrossRefPubMed
  118. Gruvberger-Saal SK, Bendahl PO, Saal LH, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res. 2007; 13(7): 1987–1994.
    CrossRefPubMed
  119. Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006; 17(5): 818–826.
    CrossRefPubMed
  120. Newby JC, Johnston SR, Smith IE, et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997; 3(9): 1643–1651.
    PubMed
  121. Arpino G, Green SJ, Allred DC, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998; 4(1): 7–12.
    PubMed
  122. Bonifazi M, Franchi M, Rossi M, et al. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. Breast. 2014; 23(5): 573–578.
    CrossRefPubMed
  123. Gianni L, Dafni U, Gelber RD, et al. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12(3): 236–244.
    CrossRefPubMed
  124. Cameron D, Piccart-Gebhart M, Gelber R, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 2017; 389(10075): 1195–1205.
    CrossRef
  125. Ministerstwo Zdrowia. Programy lekowe. Choroby onkologiczne. https://www.gov.pl/web/zdrowie/choroby-onkologiczne.
  126. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. The Lancet. 2019; 393(10191): 2591–2598.
    CrossRef
  127. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25(25): 3808–3815.
    CrossRefPubMed
  128. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23(31): 7811–7819.
    CrossRefPubMed
  129. Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat. 2019; 177(2): 237–250.
    CrossRefPubMed
  130. Kataoka A, Iwamoto T, Tokunaga E, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016; 160(1): 163–172.
    CrossRefPubMed
  131. Partridge AH, Hughes ME, Warner ET, et al. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016; 34(27): 3308–3314.
    CrossRefPubMed
  132. Goldhirsch A, Ingle JN, Gelber RD, et al. Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20(8): 1319–1329.
    CrossRefPubMed
  133. Cardoso F, Loibl S, Pagani O, et al. European Society of Breast Cancer Specialists. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012; 48(18): 3355–3377.
    CrossRefPubMed
  134. Gianni L, Dafni U, Gelber RD, et al. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12(3): 236–244.
    CrossRefPubMed
  135. Dutta SW, Volaric A, Morgan JT, et al. Pathologic Evaluation and Prognostic Implications of Nodal Micrometastases in Breast Cancer. Semin Radiat Oncol. 2019; 29(2): 102–110.
    CrossRefPubMed
  136. Ignatov T, Eggemann H, Burger E, et al. Hormone receptor status does not alter the effect of trastuzumab in breast cancer. Endocr Relat Cancer. 2016; 23(5): 349–355.
    CrossRefPubMed
  137. Keegan THM, Press DJ, Tao Li, et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 2013; 15(5): R95.
    CrossRefPubMed
  138. Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol. 2016; 8(6): 429–449.
    CrossRefPubMed
  139. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003; 95(5): 353–361.
    CrossRefPubMed
  140. Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008; 29(2): 217–233.
    CrossRefPubMed
  141. Bellon JR, Guo H, Barry WT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015; 372(2): 134–141.
    CrossRefPubMed
  142. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009; 27(36): 6129–6134.
    CrossRefPubMed
  143. Helwick C. Final Analysis of BCIRG-006 Supports Use of Non- Anthracycline-Containing Regimen in Treatment of Women With Early Breast Cancer; 2016. https://www.ascopost.com/issues/march-10-2016/final-analysis-of-bcirg-006-supports-use-of-nonanthracycline-containing-regimen-in-treatment-of-women-with-early-breast-cancer/.
  144. Burstein HJ, Piccart-Gebhart MJ, Perez EA, et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012; 30(18): 2179–2182.
    CrossRefPubMed
  145. Veitch Z, Khan OF, Tilley D, et al. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer. J Natl Compr Canc Netw. 2019; 17(1): 47–56.
    CrossRefPubMed
  146. Willson ML, Burke L, Ferguson T, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2019; 9: CD004421.
    CrossRefPubMed
  147. Dewar J, Arriagada R, Benhamou S, et al. Local relapse and contralateral tumor rates in patients with breast cancer treated with conservative surgery and radiotherapy (institut gustave roussy 1970–1982). Cancer. 1995; 76(11): 2260–2265, doi: 10.1002/1097-0142(19951201)76:11<2260::aid-cncr2820761113>3.0.co;2-d.
  148. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011; 29(29): 3885–3891.
    CrossRefPubMed
  149. Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat. 2019; 177(2): 237–250.
    CrossRefPubMed
  150. Dang CT, Yu AF, Jones LW, et al. Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. J Clin Oncol. 2016; 34(10): 1030–1033.
    CrossRefPubMed
  151. Ciulkin K, Czerwiński A, Dagiel J. et al. Świadczenia onkologiczne I kardiologiczne w Polsce – podejście ilościowe do oceny jakości leczenia i szacowania potrzeb. Więckowska B (ed.). publikacja współfinansowana przez Unię Europejska w ramach Europejskiego Funduszu Społecznego, Warszawa 2015.
  152. Meier J, Dietz A, Boehm A, et al. Predicting treatment process steps from events. J Biomed Inform. 2015; 53: 308–319.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna